Yajing Chen Net Worth

The estimated Net Worth of Yajing Chen is at least $323 Thousand dollars as of 14 August 2024. Yajing Chen owns over 1,250 units of Zai Lab stock worth over $322,773 and over the last few years Yajing sold ZLAB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Yajing Chen ZLAB stock SEC Form 4 insiders trading

Yajing has made over 6 trades of the Zai Lab stock since 2023, according to the Form 4 filled with the SEC. Most recently Yajing exercised 1,250 units of ZLAB stock worth $26,963 on 14 August 2024.

The largest trade Yajing's ever made was exercising 6,250 units of Zai Lab stock on 25 June 2024 worth over $134,813. On average, Yajing trades about 1,846 units every 46 days since 2023. As of 14 August 2024 Yajing still owns at least 14,964 units of Zai Lab stock.

You can see the complete history of Yajing Chen stock trades at the bottom of the page.

What's Yajing Chen's mailing address?

Yajing's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.

Insiders trading at Zai Lab

Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis, and John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.

What does Zai Lab do?

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve

Complete history of Yajing Chen stock trades at Zai Lab

Zai Lab executives and stock owners

Zai Lab executives and other stock owners filed with the SEC include:

• Dr. Ying Du,
  Founder, Chairperson & CEO
• Frazor Titus Edmondson III,
  Chief Legal Officer & Corp. Sec.
• Tao Fu,
  Chief Strategy Officer
• Ki Chul Cho,
  Chief Financial Officer
• Dr. Alan Bart Sandler M.D.,
  Pres & Head of Global Devel. in Oncology
• Leon Moulder,
  Independent Director
• William Lis,
  Independent Director
• Chen Kai-Xian,
  Independent Director
• John Diekman,
  Independent Director
• Peter Wirth,
  Director
• Nisa Leung,
  Director
• Hei Yongjiang,
  Chief Medical Officer, Oncology
• Harald Reinhart,
  Chief Medical Officer, Autoimmune and Infectious Diseases
• William Liang,
  Chief Commercial Officer
• F. Ty Edmondson,
  Chief Legal Officer
• Valeria Fantin,
  Chief Scientific Officer
• Jonathan Wang,
  Senior Vice President, Head of Business Development
• James Yan,
  Executive Vice President, Preclinical Development and Program & Portfolio Management
• Ning Xu,
  Executive Vice President, Head of Clinical and Regulatory
• Billy Cho,
  Chief Financial Officer
• Fu Tao,
  President, Chief Operating Officer, Director
• Du Ying,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Danielle Halstrom,
  Sr. VP & Global Head of Communications
• Ann E. Beasley J.D.,
  Chief Compliance Officer
• Dr. Harald Reinhart M.D.,
  Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
• Dr. James Yan DABT, M.D., Ph.D.,
  Chief Operating Officer of R&D
• Dr. Jonathan J. Wang M.B.A., MBA, Ph.D.,
  Exec. VP & Head of Bus. Devel.
• Dr. Ning Xu M.D.,
  Exec. VP & Head of Clinical Operations
• Ann Beasley,
  Chief Compliance Officer
• Scott W Morrison,
  
• Richard Gaynor,
  
• Rafael Amado,
  See Remarks
• Michel Vounatsos,
  
• William Ki Chul Cho,
  Chief Financial Officer
• Alan B. Sandler,
  Head of Global Dev., Oncology
• Yi Liang,
  CCO & President, Greater China
• Joshua L Smiley,
  See Remarks
• Yajing Chen,
  Chief Financial Officer